Showing 759 news articles about Hepatitis C treatment

Filters Content type: Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment

Abstracts Have Been Posted: International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL)

Editor's pick
HCV New Drugs Research
9 April 2015
Hepatitis C treatment

WHO Issues Guideline For Manufacturers Of Generic Hepatitis C Medicine

Editor's pick
Intellectual Property Watch
8 April 2015
Hepatitis C treatment

Cipla announces the launch of generic drug Sofosbuvir in India under the brand name ‘Hepcvir`

Editor's pick
Cipla press release
31 March 2015
Hepatitis C treatment

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C

Editor's pick
Gilead press release
31 March 2015
Hepatitis C transmission & prevention

World first trials for hepatitis C wonder drug in Sydney's maximum security jails

Editor's pick
Sydney Morning Herald
30 March 2015
Access to healthcare

KEI Europe asks Romanian government to issue compulsory licences on hepatitis C medicines

Editor's pick
Knowledge Ecology International
23 March 2015
Access to healthcare

Indian generic companies should reject Gilead’s controversial hepatitis C ‘Anti-Diversion’ programme

Editor's pick
MSF
19 March 2015
Access to healthcare

Gilead to require proof of citizenship to buy Sovaldi in poor countries

Editor's pick
Fierce Pharma
19 March 2015
Hepatitis C treatment

Bristol-Myers Squibb Co. Is Back in the Hepatitis C Race

Editor's pick
Motley Fool
18 March 2015
Hepatitis C treatment

Hepatitis C Drugs Will 'Strain Budgets': Study

Editor's pick
WebMD
17 March 2015
Hepatitis C treatment

Gilead's hepatitis C drugs largely cost-effective in US - study

Editor's pick
Reuters
17 March 2015
Hepatitis C treatment

Hepatitis C pills drive surge in U.S. drug costs: report

Editor's pick
Reuters
12 March 2015
Hepatitis C treatment

Here Is Why Gilead Sciences, Inc. Is Still Doing Better Than AbbVie Inc

Editor's pick
Bidness
10 March 2015
Access to healthcare

$10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh

Editor's pick
Bloomberg
9 March 2015
Access to healthcare

EECA CAB positions in regards to Janssen, BMS, Gilead and ViiV policy

Editor's pick
EATG
9 March 2015
Improving HIV care

NIH-led study to assess community-based hepatitis C treatment in Washington, D.C.

Editor's pick
EurekAlert
9 March 2015
Hepatitis C treatment

Natco Pharma ties up with Gilead on hepatitis C drugs

Editor's pick
Reuters
4 March 2015
Hepatitis C treatment

HCV Drugs Costly but Cure Might Not Be

Editor's pick
MedPage Today
4 March 2015
Hepatitis C treatment

Gilead's Harvoni gains NICE yes - but won't face funding delay

Editor's pick
PM Live
3 March 2015
Hepatitis C treatment

Delay HCV Tx and Watch Patients Die

Editor's pick
MedPage Today
2 March 2015
Hepatitis C treatment

Doctor Panel to Weigh Hepatitis C Drugs’ Costs in Guidelines

Editor's pick
Bloomberg
2 March 2015
Hepatitis C treatment

NICE guidance recommends sofosbuvir (Sovaldi, Gilead Sciences) and simeprevir (Olysio, Janssen) for treating hepatitis C

Editor's pick
NICE press release
26 February 2015
Hepatitis C treatment

Cost-Effectiveness of Immediate Hepatitis C Treatment in Early Disease Analyzed

Editor's pick
HCP Live
20 February 2015
Hepatitis C treatment

amfAR Report Examines Controversial Pricing of Hepatitis C Treatment

Editor's pick
amfAR
19 February 2015